Peptides folded through interwoven disulfides display extreme biochemical properties and unique medicinal potential. However, their exploitation has been hampered by the limited amounts isolatable from natural sources and the expense of chemical synthesis. We developed reliable biological methods for high-throughput expression, screening and large-scale production of these peptides: 46 were successfully produced in multimilligram quantities, and > 600 more were deemed expressible through stringent screening criteria. Many showed extreme resistance to temperature, proteolysis and/or reduction, and all displayed inhibitory activity against at least 1 of 20 ion channels tested, thus confirming their biological functionality. Crystal structures of 12 confirmed proper cystine topology and the utility of crystallography to study these molecules but also highlighted the need for rational classification. Previous categorization attempts have focused on limited subsets featuring distinct motifs. Here we present a global definition, classification and analysis of > 700 structures of cystine-dense peptides, providing a unifying framework for these molecules.
P eptides are differentiated from proteins on the basis of their smaller size of generally fewer than ~50 residues. Because of their size, peptides cannot form sufficient cooperative interactions and thus usually do not adopt the stable, defined structures achieved in proteins through well-packed hydrophobic cores. Exceptions include peptides that alternately organize around cores of tightly packed disulfides ( Fig. 1a ), which often confer extreme thermal, chemical and proteolytic stability [1] [2] [3] [4] . Archetypes of such peptides, with cores of at least three cystines, include 'inhibitor cystine knot peptides' , or knottins, and the closely related 'cyclic cystine knot peptides' , or cyclotides 5, 6 . Examples include venom toxins from cone snails, spiders and scorpions; plant protease inhibitors; and antimicrobial defensins. Knottins and cyclotides are topologically pseudoknotted, with one cystine (the 'knotting' cystine) crossing through the macrocycle formed by the other two cystines (the 'bracketing' cystines) and the interconnecting backbone, which often contains additional accessory cystines (Fig. 1b ). Proteins can also be pseudoknotted through intrachain cystines, e.g., 'growth-factor cystine knots' 7, 8 (GFCKs; Fig. 1c ). However, GFCK intrachain cystines do not dominate the fold of the protein, which includes a conventional hydrophobic core distinct from the structures of knottins and cyclotides.
Natural knottins and cyclotides have demonstrated many properties beyond stability, which are useful in clinical applications; these properties include the potential for oral delivery, cell penetration and tumor homing 3, 4, 9 . Inherent pharmacological properties can also include analgesic, antihelminthic, antimicrobial, antitumor, insecticidal or ion-channel-modulatory activities 5 . These peptides are intermediate in size between protein biologics and conventional small-molecule drugs; hence, they are potentially small enough to penetrate a variety of tissues and solid tumors but large enough to enable protein-like ligand specificity and affinity. Approved drugs exploiting these properties include ziconotide (Prialt), based on a cone-snail-venom knottin; linaclotide (Linzess), based on Escherichia coli heat-stable enterotoxin; and plecanatide (Trulance), based on human uroguanylin 10 .
Overall, the minimal common elements defining this class of molecules are short sequences constituting independent folding domains and having a high density of cystines (i.e., at least three). We refer to this categorization as 'cystine-dense peptides' (CDPs), drawing a distinction between CDPs and larger proteins with cystine-knotted elements, such as GFCKs. Inspired by these peptides' unique folds and their potential for clinical application-as well as the success of ziconotide, linaclotide, plecanatide and tozuleristide (Tumor Paint) 11 , a tumor-homing, fluorophore conjugate of the scorpion knottin Chlorotoxin (CTX)-we sought to more fully explore and exploit these molecules. However, although these peptides are generally amenable to chemical synthesis, and some have been expressed recombinantly, a major impediment to exploiting this unique pharmacomolecular space has been the lack of a reliable high-throughput expression platform.
Here we report biologic production of over 700 CDPs and exhaustive biochemical characterization of 46 CDPs demonstrating unique properties. We optimized crystallographic methods for elucidating CDP structures. Structural analyses highlighted another impediment to understanding this fold space: the absence of a unified, global scheme for classifying CDPs. Because there are many examples of structured cystine-rich peptides that are not knottins or cyclotides, or even knotted, we propose a structure-based classification scheme unifying and framing an analysis of a complete catalog of available CDP structures.
Results
CDP sequence-based definition. Inspection of the Protein Data Bank (PDB) 12 and homologous sequences from natural sources suggested a CDP-defining motif comprising: (i) six or more cysteine residues in a span from 13 to 81 residues long and not recognizable as a cytoplasmic protein or domain, a zinc-finger protein or a GFCK; and (ii) a constrained distribution of cysteines, Cys-X [0] [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] -Cys-X [0] [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] -Cys-X [0] [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] -Cys-X [0] [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] -Cys-X [0] [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] -Cys (where X represents any amino acid). To confirm formation of cystines, the candidate CDP should be embedded in a sequence with a recognizable leader peptide, e.g., by using SignalP 13 ; annotated as a secreted or integral membrane protein; or experimentally shown to contain specific cystines. CDPs may be embedded in larger proteins or in tandem arrays (some examples have more than 40 (refs 14,15 )) but should comprise an independent folding unit.
Applying these rules to the PDB yielded a continuum of structures, though adding the criterion of a minimal 'cysteine density' , with at least 12% cysteine content in the span including the bounding cysteines, satisfactorily separated CDPs from small proteins with emergent hydrophobic cores. This threshold density is approximately ten-fold higher than the average for all proteins 16, 17 . In the PDB, as of April 2017, there were 775 experimentally determined structures with domains conforming to this motif, excluding wholly synthetic, designed sequences and including 422 knotted CDPs, 203 nonknotted CDPs with three cystines and 150 nonknotted CDPs with more than three cystines (Supplementary Table 1 ).
CDP biologic production.
To develop a biologic expression platform for CDPs, we selected a target set of 100 proteins (Supplementary Table 2 ). We concentrated on CDPs similar or and a nonknotted cystine-containing peptide, Elafin (c), all determined as part of this work. The structures, shown in backbone representation, with cysteine side chain sulfur atoms shown as spheres, demonstrate the degree to which cystines dominate the cores of these structured peptides. The backbone and cysteine side chain atoms are colored from blue to red from the N to C terminus, highlighting the cystine connectivity and pseudoknot topology characteristic of knottins and related peptides. The topology is represented as u-v, [w-x], y-z, where w-x is the knotting cystine, and u-v and y-z are the bracketing cystines. CTX, like many knotted CDPs, has an accessory cystine, circled in red, in addition to the three core cystines defining the pseudoknot element. d, A typical dimeric GFCK, human nerve growth factor (NGF), shown in cartoon representation, with one monomer colored gray and the other monomer colored as in a. identical to previously studied CDPs, largely spider-and scorpion-venom components, to validate success; however, we also included some simpler two-cystine, non-CDP sequences (e.g., Hefutoxin) to phase in the magnitude of the challenge. We abandoned initial attempts to produce CDPs in bacterial expression systems in favor of mammalian secretion-pathway-based systems, which incorporate folding chaperones and extensive quality-control machinery and thus dramatically improved success rates. CDPs produced in mammalian cells were also free of contaminating endotoxins, thereby streamlining in vivo applications. CDPs were ultimately most successfully produced through a variation of the Daedalus lentivirus transduction system 18 in HEK293 cells, with Siderocalin (Scn) fusion-protein partners 19 to foster folding and increase yield ( Supplementary Fig. 1 ). An improved version of tobacco etch virus (TEV) protease [20] [21] [22] [23] , SuperTEV, was also developed to complement Daedalus expression ( Supplementary Fig. 2 ). SuperTEV showed activity identical to that of TEV but was more stable, did not require reducing agents for stability and could be functionally expressed in mammalian cells.
Because isolated CDPs displayed anomalous behavior in reduced/ nonreduced comparative PAGE and size-exclusion chromatography, reverse-phase chromatography (RPC) was used for preparative purification after cleavage, final purity assessment and biochemical characterization. RPC is extremely sensitive to any chemical heterogeneity in a preparation, and it can also detect the presence of chemically identical but conformationally distinct isoforms. Expression of a CDP was considered successful only if the final RPC traces showed only a single dominant peak under both oxidizing and reducing conditions, thus indicating a single folding state, and the absence of proteolysis or heterogeneity of any kind, including conformational heterogeneity ( Fig. 2a and Supplementary Dataset 1). Prior studies of CDP synthesis (e.g., ref. 24 ) have yielded preparations that were biologically functional but displayed complex RPC traces, which have been suggested to indicate the presence of multiple conformers that do not interchange on the RPC timescale. Distinct metastable conformers of a CDP may not, for instance, all interact equivalently with a target ion channel, thus complicating analyses of less stringently produced peptides. We chose to apply the most rigorous threshold for success, requiring absolute homogeneity. Of the 100 targets, 46 were successfully produced under these stringent criteria (Supplementary Dataset 1). For example, CDP #11 showed nearcomplete resistance to reduction, but CDP #17 was a doublet under nonreducing conditions and hence did not meet our quality-control criteria ( Fig. 2a ). This system is amenable to high-throughput, pilotscale expression screening on automated robotic platforms as well as affordable preparative-scale production, with final yields of up to 10 mg/L at a 2-L culture scale. The high-throughput platform processed hundreds of CDPs per week, yielding up to 20 μ g at the 1-mL culture scale. These amounts were sufficient to evaluate proper folding through analytical RPC by applying the same stringent criteria as above. We determined that another 678 CDPs (55%) out of an additional list of 1,232 targets were expressible, by using the highthroughput approach ( Supplementary Table 3 ). These additional targets more broadly sampled CDPs from plants, arthropods and other taxa; 872 had less than 75% identity to a CDP in the PDB.
CDP biochemical and structural characterization.
To further explore the previously reported extreme biochemical stability of CDPs 4,6,7 , we tested the 46 successfully produced CDPs under a battery of conditions that would be expected to denature or degrade conventional globular proteins, including extended incubation under reducing conditions or at high temperatures, and proteolytic digestion (Supplementary Dataset 1). Most of the 46 CDPs showed resistance to some combination of these conditions, but several showed truly exceptional stability, including two knotted CDPs that were completely resistant to all conditions tested (Supplementary Dataset 1). CD spectra were collected from the 46 successfully produced CDPs to evaluate secondary-structure content ( Fig. 2b and Supplementary Dataset 1). The range observed included spectra showing very limited secondary-structure content, in agreement with known homologous structures. The ultimate confirmation of proper cystine formation in a CDP is experimental determination of its three-dimensional structure. Most isolated CDP structures available in the PDB were determined by NMR, partly because of the perception that CDPs are inherently difficult to crystallize. Crystallography has previously been used primarily, but very effectively, to determine structures of complexes between CDPs and binding-partner proteins. However, access to an efficient expression system allowed for large-scale production of highly purified CDPs that could be highly concentrated (to ≥ 80 mg/mL), thereby enhancing crystallizability. Of the 46 successfully expressed CDPs, 12 were crystallized (26% success rate, one in two crystal forms) and used to determine structures (Tables 1 and 2, Supplementary Table 4 and Supplementary Fig. 3 ). Initial phases were determined either by molecular replacement (MR) or sulfur single-wavelength anomalous diffraction (sSAD) 25 , by using copper Kα radiation to maximize the anomalous signal. With optimized procedures, sSAD proved to be an extremely effective approach for CDP structural analysis, providing completely unbiased initial phases and more direct, detailed information about sulfur substructure. These new structures all showed the expected overall cystine connectivity and topology, on the basis of comparisons with previously determined homologous structures, thus validating the expression platform. However, many detailed structural differences were found when these crystal structures were compared with previous NMR structures (e.g., CTX; Fig. 2c ), particularly in the arrangement of the cystine core, the key defining element of CDP structure. The disparity in structural details is also likely to explain the inability to use the as-deposited CTX NMR structure as an MR search model to phase the crystallographic data, which required computational remodeling with Rosetta 26 to generate a successful search model. A number of CDP crystals yielded multiple independent views of their structures ( Supplementary Table 4 ), thus providing additional information about structural rigidity/flexibility ( Fig. 2d ) and quaternary structure ( Fig. 2e ). In the most extreme cases, the whey acidic protein-type, four-disulfide-core peptide Elafin (target #4, a human, nonknotted CDP) crystallized with 18 copies in the asymmetric unit (AU), thus demonstrating the extraordinary structural rigidity possible in CDPs. The γ -KTx 2.2 potassium-channel toxin (target #48, a knotted CDP from the venom of the Manchurian scorpion) crystallized in the same tetrameric state, with 20 copies in total in the AUs of two different crystal forms. Although prior NMR structural anal-yses have suggested inherent flexibility or the presence of multiple conformers in solution for some CDPs (e.g., Supplementary Fig. 3 ), the high degree of structural conservation observed among multiple views in CDP crystal structures conversely favors the adoption of a single rigid structure for these examples.
CDP ion-channel modulation. Many natural venom and toxin
CDPs have been reported to modulate ion-channel activity 4 , and our initial target set of CDPs included many related molecules. To assess channel activity, both to verify production of functional CDPs and to identify additional specificities/activities, the selectivity profiles of 37 successfully expressed CDPs were assessed with a commercial electrophysiological assay on a panel of 20 human ion channels ( Supplementary Fig. 4 ). All showed some activity toward at least a subset of ion channels, predominantly potassium channels. Although many of the 37 had not been previously characterized or had been tested on a more focused set of channels, the agreement between our results and the limited prior results was very good, thus reinforcing the utility of our CDP production/ characterization platform.
CDP structure-based classification. Coupling optimized CDP crystallography with robust expression platforms enables full determination of the boundaries of CDP fold space, if CDPs can be identified on the basis of sequence and classified on the basis of structure. However, we encountered several practical problems in applying our CDP-defining motif to larger databases to fully catalog candidate CDPs on the basis of sequence. To ensure cystine formation, the cluster of cysteines defining a candidate CDP should be localized in a protein ectodomain. Although the presence of recognizable leader peptides worked well for type I transmembrane proteins, problems were encountered with reliably localizing CDPs to ectodomains in type II and type III transmembrane proteins, and annotations lacked sufficient standardization to allow for confident substitution. Identifying the bounding cysteines in a cluster of cysteines in a sequence was also problematic, because the number of cysteines in CDPs can be highly variable, and can even be an odd number when some CDPs covalently link to another peptide through an interchain cystine (e.g., PDB 1BUN 27 ). Likewise, no sequence-based rules were discerned that could rigorously identify the full sequence boundaries of CDPs outside of the bounding cysteines. Therefore, it was not possible to prospectively generate a complete CDP catalog based solely on sequence. Previous proposed structural classification schemes [28] [29] [30] , sometimes also relying on inconsistent functional annotations, were too narrow to be applied globally, thus also precluding a unified classification based solely on structure. Our CDP definition does not require that the fold contain a cystine pseudoknot; however many CDPs do contain a cystine pseudoknot, thus defining a subset: the knotted CDPs. CDPs are defined as having at least three cystines, the minimum number required to generate a pseudoknotted topology. Stepping back, we found that inspection of the available CDP structures did establish a global, unified, structure-based CDP-classification scheme by focusing solely on the arrangement of the three core cystines defining a CDP. In contrast, previous approaches have drawn distinctions based on the total number of cystines, intercysteine-loop lengths or secondary-structure content. The first level of our proposed classification was determined on the basis of cystine connectivity ( Fig. 3a) . Numbering the cysteines in the three-cystine core or knotting element sequentially from 1 to 6 yields 15 theoretically possible connectivity classes, and archetypical knottins and most GFCKs fell into the 1-4, 2-5, 3-6 class. This class was, by far, the most frequently observed among knotted CDP structures in the PDB (298 examples) and thus is referred to as 'canonical' . Four other connectivity classes were observed in deposited knotted CDP structures, with variable representation, and nine additional connectivity classes were observed exclusively in deposited nonknotted CDPs with three cystines (Fig. 3b ). One connectivity class (1-6, 2-3, 4-5) was not observed in any natural CDPs, although it was found in wholly synthetic designed CDPs (e.g., PDB 5JI4 (ref. 31 )). Nonknotted CDPs with more than three cystines cannot be assigned to comparable connectivity classes, because the focus subset of three cystines cannot be defined and numbered in the same way in the absence of a knotting element and hence were included together in a separate class, 'z' .
The second level of classification, applicable to knotted CDPs, was based on cystine topology, i.e., among the three core cystines comprising the knotting element, ignoring variable accessory cysteines, which cystine pseudoknots the fold (Fig. 3b) . In any connectivity class, denoted u-v, w-x, y-z to indicate the core-cystine connectivity, there are three theoretical topologies, each with a different knotting cystine. CDP connectivity class plus knotting topology generated a structure-based knotted CDP type, represented u-v, w-x, [y-z], where the knotting cystine is indicated by brackets. Nonknotted CDPs with three cystines were denoted solely by connectivity class (u-v, w-x, y-z). Under this nomenclature, archetypical knottins were classified as type 1-4, 2-5, [3] [4] [5] [6] , where structural homology cannot be assumed or reliably modeled 36, 37 ,. The sequence diversity in CDP space was broad enough to preclude useful clustering or correlating sequence with structure. However, limiting the analysis to knotted CDPs showed much better sequence clustering, at identity levels supporting potential linkage of sequence with structure. c, Sequence-based phylogram of the 422 knotted CDPs in the PDB, colored by knotted-CDP structure-based type, tabulated at left. In the legend, CDP type is divided into canonical versus noncanonical cystine connectivity, and common connectivities are boxed. The locations of pacifastin (yellow arc, labeled 'P') and hitchin (black-to-gray arcs, labeled by cluster number) clusters defined by structural homology (Fig. 5 ) are indicated, showing strong sequence similarity between members of the pacifastin and hitchin cluster #1 subsets, but weaker similarities between other hitchin clusters and knotted CDP types in general. The sequence identity between the knottins in the sub-branch associated with the cluster #1 hitchins and the cluster #1 hitchins was ~26%, and the minimal pairwise identity within the cluster #1 hitchins was ~50%. Knotted CDP types are interspersed throughout the phylogram, with types typically clustering only very locally.
'shanks' (a shank is another kind of knot used to shorten a rope); and rare type [1-4], 2-5, 3-6 knotted CDPs as 'shankins' . Though far fewer knotted CDP structures have noncanonical connectivities, examples of nine additional knotted types were found. The distribution between different connectivity classes (nonknotted CDPs) and types (knotted CDPs) was very uneven, dominated by knottins, z-class CDPs and hitchins (Fig. 3c ). This proposed scheme provides an unambiguous method for CDP structural classification and comparison independent of source organism, sequence similarity or functional annotation. Its advantages include avoiding broad annotations, such as 'defensin' , which denotes cysteine-rich, cationic antimicrobial peptides but also encompasses a wide range of structurally dissimilar knotted and nonknotted CDPs, including many hitchins and knottins. Although it is robust and global, our proposed classification scheme cannot be applied in the absence of experimental determination or reliable modeling of CDP structure. However, structure type can correlate with function: hitchins predominated among multiply resistant CDPs. Global pairwise sequence comparisons among all 775 CDPs in the PDB showed very limited similarity (Fig. 4a ), thus precluding grouping or clustering across all CDPs to discern sequence-structure relationships. However, limiting the analysis to knotted CDPs revealed sequence-similarity scores meaningful for potentially identifying structural homology (Fig. 4b) . Nonetheless, sequencebased phylograms of knotted CDPs did not reveal global sequence/ structure clustering; for example, knottin and hitchin branches were inseparably interwoven (Fig. 4c) . Exceptions included lim-ited subsets of clearly structurally related knotted CDPs, such as the pacifastins, which are type 1-4, 2-6, [3] [4] [5] knotted CDP serine protease inhibitors from arthropods (global superposition r.m.s. deviation (r.m.s.d.) = 0.35 Å; Fig. 5a ). In addition to the pacifastin cluster, available CDP structures were aligned to group CDPs into four more recognizably similar clusters: a cluster (#1) of α β β three-cystine hitchins from scorpions (r.m.s.d. = 0.55 Å; Fig. 5b ); a cluster (#2) of β α β β four-disulfide-containing hitchins from scorpions (r.m.s.d. = 0.60 Å; Fig. 5c ); a cluster (#3) of β α β β four-disulfidecontaining hitchins from plants (r.m.s.d. = 0.46 Å; Fig. 5d ); and a cluster (#4) of three-disulfide-containing hitchins from various taxa (r.m.s.d. = 0.65 Å; Fig. 5e ). These results echo findings from previous studies identifying knotted CDP-subtype structural clusters, e.g., the Möbius and Bracelet clusters of the type 1-4, 2-5, [3] [4] [5] [6] cyclotides 6 and, more broadly, the 'cysteine-stabilized α β defensins' 29 . These results also validated our proposed classification focused on core cystines by revealing hitchin structural homologies despite the presence of variable accessory cystines.
Structure-based sequence alignments yielded motifs potentially useful for prospectively identifying candidate structural homologs of the pacifastins (Fig. 5f , thus extending prior studies 32 ) and one hitchin subset (Fig. 5g) . Sequence conservation for the other three hitchin subsets was more limited, or even unrecognizable, despite considerable structural similarity (Fig. 5h-j) . Even more simplistic sequence-based metrics, such as intercysteine-loop lengths, did not robustly differentiate between knottins and hitchins (Fig. 5k ), or between hitchin subsets (Fig. 5l) . In contrast to the knottins, N  1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30   1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30   1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  36  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53   1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  36  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53   1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  36  39  40  41  42  43  44  45   54  55  56  57 these hitchin-subset clusters all displayed conserved secondarystructure content, with very similar α β β or β α β β folds, as echoed in their respective CD spectra (Fig. 5m,n) . Normalized CD spectra from all 14 successfully expressed knottins showed a wide range of secondary-structure compositions, and the spectra from all 16 successfully expressed hitchins showed a fairly narrow range of secondary-structure compositions, in agreement with the greater degree of structural homology observed among hitchins in general. Taxonomy-based phylogenies ( Supplementary Fig. 5 ), although likely to be affected by experimenter selection bias, showed very uneven distributions: among knotted CDPs, examples from arachnids, magnoliopsids, mammals and gastropods, at the class level, predominated. Nonknotted CDPs were predominately from mammalian (class) and primate (order) sources, whereas knotted CDPs were predominately from arachnids, mostly scorpions.
Discussion
We developed an efficient, reliable platform for large-scale production and high-throughput expression screening of endotoxin-free CDPs. The pipeline incorporates multiple steps to stringently validate proper folding (including structure determination by X-ray crystallography) and to assay biological function (including ionchannel inhibition). Starting from a purely sequence-based CDP definition, we also developed a proposed robust, purely structurebased classification system for CDPs, framing an exhaustive analysis of these molecules. The classified CDPs encompassed a wide range of diverse molecules, including epidermal growth factor-like domains, low density lipoprotein-like domains, tumor necrosis factor receptor-like domains, transforming growth factor receptor-like domains, trefoil/plexin domains, notch-repeat-like domains, resistin-like domains, osmotin-like domains, thaumatin-like proteins, disintegrins, anaphylatoxins, insect antifreeze proteins and chitinbinding penaeidins.
The most unexpected result of the analyses of CDP sequence/ structure relationships based on this classification was the very limited correlation between CDP sequence and structure type; this lack of correlation severely restricts the prospective mapping of structures on the basis of sequence alone. The next challenges will be to develop more sophisticated sequence-based tools to completely catalog CDP sequence space, and to apply these tools to guide broader sampling of CDP-structure space, more evenly across taxa, to confidently identify its boundaries. Focused studies to parse the roles of the few conserved residues in determining CDP folds are now possible with high-throughput platforms for expressing panels of sequence variants to deeply sample effects on folding. These tools together enable future exploration of CDP space for advancing basic science, through the study of an exceptional protein-fold family, and clinical application, through production and manipulation of molecules with uniquely useful properties.
Methods
Methods, including statements of data availability and any associated accession codes and references, are available at https://doi. org/10.1038/s41594-018-0033-9.
CDP production and purification. For expression of CDPs in mammalian cell lines, the Daedalus 18 expression cassette was modified to include, from the N to C terminus: a mouse Igκ leader-peptide sequence, an optimized FLAG epitope sequence 41 , a hexahistidine purification-tag sequence, the Scn fusion-partner 19 sequence, the TEV scission sequence (ENLYFQ|… ), a short glycine/serinespacer sequence and the CDP sequence. A minimum of three amino acids before the first CDP cysteine residue was found to be essential for efficient protease cleavage, thus necessitating a short glycine/serine spacer. Because CDPs are found in nonmammalian hosts, but the Daedalus system is based on production in mammalian cells, the targeted CDP sequences were checked and corrected for cryptic N-glycosylation sequences, e.g. in E. coli heat-stable enterotoxin, by mutation to generate fully functional peptides. Difficulties in defining CDP boundaries outside of the bounding cysteines probably also limited the overall success rate. CDP-encoding Daedalus lentiviruses were produced by transient transfection of suspension-adapted HEK293T cells (ATCC CRL-3216) with psPAX2 (Addgene 12260), pMD2.G (Addgene 12259) and Scn/CDP fusion-encoding vectors, by using linear 25-kDa polyethyleneimine (PEI; Polysciences). Cells were tested for mycoplasma contamination (MycoProbe; R&D Systems). For preparativescale production of CDPs, transfected cells were cultured in 5 mL of FreeStyle 293 Expression Medium (Thermo Fisher), and the culture was fed with 5 mL of FreeStyle medium supplemented with 6 mM valproic acid (Sigma-Aldrich) after 24 h. Lentivirus was harvested 44 h after medium was filtered through a 0.45-µ m Steriflip filter (Millipore). HEK293F cells (Thermo Fisher) were transduced with 1 mL of lentivirus stock added dropwise in 125-mL shake flasks with 1 × 10 7 cells in 9 mL of FreeStyle medium. After 6 h, the culture was fed with 20 mL of Freestyle medium. Transduced cells were expanded until a total culture size of 4 L at ~5 × 10 6 cells/mL was reached or viability began to drop. CDP fusion proteins were purified by immobilized metal-affinity chromatography (IMAC) 42 with HisTrap FF crude columns (GE) on an ÄKTA Pure FPLC system (GE). The CDP was cleaved from the Scn fusion partner by protease digestion, separated from unwanted digestion products by RPC (0.1% (w/w) TFA in water versus 0.1% (w/w) TFA in acetonitrile) on a Tricorn 10/150 column packed with Source 15RPC resin (GE), by using an ÄKTA Pure FPLC system, and lyophilized for storage.
The incorporated TEV-cleavage sequence in the fusion construct leaves an exogenous GS-dipeptide stump from the linker at the N terminus of the recombinant CDP. Expressed CDPs were confirmed by direct-infusion electrospray mass spectrometry (ES-MS) on an LTQ-OrbiTrap mass spectrometer (Thermo Electron). For ES-MS, CDPs were dissolved in water at 1 mg/mL, then desalted and purified through C18 ZipTip chromatography (EMD Millipore). Cystine formation was confirmed by analysis of the m/z monoisotopic distribution and determination of net charge, and by crystallography. Calculated and observed m/z values are listed in Supplementary Table 2 .
High-throughput pilot-scale expression screening was carried out in an analogous but scaled fashion, with viral production performed in 2-mL deep-well blocks (Axygen), producing 1 mL of lentivirus stock per well. 50-100 μ L of the lentivirus stock was used to transduce ~2 × 10 6 HEK293F cells in 1 mL of Freestyle medium in deep-well blocks. Transduction was confirmed by flow cytometry after 36 h, with a NovoCyte cytometer (ACEA), and cultures were fed with 6 mM valproic acid after 120 h. Culture supernatants were harvested after 7 d and transferred to a Protino purification plate (Machery-Nagel) containing 100 μ L of Ni-NTA IMAC resin (GE) per well, washed and eluted. Eluted CDPs were cleaved and analyzed by RPC, as described above. For high-throughput expression screening of the broader set of 1,232 CDPs, termini were chosen three residues beyond the bounding cysteines in the embedding sequence, or the native termini of the peptide if the sequence did not extend that far.
Biochemical characterization.
To determine resistance to high temperatures, CDPs were incubated at 0.5 mM in PBS at 75 °C or 100 °C for 1 h and pelleted, and the supernatant was analyzed with RPC. To determine resistance to proteolytic digestion, CDPs were mixed with 50 U of porcine pepsin (Sigma-Aldrich P7012) in simulated gastric fluid 43 at pH 1.05, or 50 U of porcine trypsin (Sigma-Aldrich 6567) in PBS, incubated for 30 m at 37 °C and analyzed with RPC. Oxidized and reduced forms (prepared through addition 10 mM DTT) were compared. CD spectra were measured with a Jasco J-720W spectropolarimeter in a cell with a 1.0-mm path length, and CDPs were diluted into 20 mM phosphate buffer, pH 7.4, at a concentration of 15-25 μ M.
Crystallization and crystallography. CDPs were resuspended at a target concentration of 80 mg/mL. Crystallization screening was performed at room temperature through vapor diffusion, with 1:1 protein solution/reservoir solution sitting drops, set up with the Nextal JCSG+ , PEGs and AmSO 4 factorial suites (Qiagen), and submicroliter robotics (TTP Labtech mosquito). Diffraction data were collected from single crystals with a Rigaku MicroMax-007 HF home source or beamline 5.0.1 at the Advanced Light Source (Lawrence Berkley National Laboratory). For sSAD phasing, Bijvoet-pair measurement was optimized by collecting data through 5° wedges with alternating phi rotations of 180°, in 1° oscillations. Data were reduced and scaled with HKL2000 (ref. 44 ). Initial phases were determined by MR with PHASER 45 in the CCP4 program suite 46 , by using homologous structures from the PDB as search models (as is, or after computational refinement in the Rosetta suite 26 ), or by sSAD 25 , determining sulfur substructures with SHELX 47 . Iterative cycles of model building and refinement were performed with COOT 48 and REFMAC 49 ; structure validation was performed with MolProbity 50 . Crystallization and cryopreservation conditions, and additional phasing and structure validation information for 10 of the 12 CDP structures are detailed in Supplementary Table 4 . The crystal-structure determinations of CDPs #11 and #29 will be described elsewhere.
Ion-channel activity assays. The selectivity profile of 37 CDPs selected from the 46 successfully expressed peptides on a panel of 20 ion channels was assessed with a commercial electrophysiological assay platform (IonWorks Barracuda, Charles River) 51, 52 . Peptides were screened in duplicate at final concentrations of 20 μ M and 200 nM, as determined by amino acid analysis, and diluted into HEPES-buffered physiological saline (HBPS). HEK293 or CHO cells from the American Type Culture Collection were transfected with expression constructs for the appropriate ion channels before use. HEK293 cells were grown in Dulbecco's Modified Eagle's Medium/nutrient Mixture F-12, and CHO cells were cultured in Ham's F-12 medium. All cultures were supplemented with 10% fetal bovine serum, 100 U/ mL penicillin G, 100 μ g/mL streptomycin sulfate and the appropriate selection antibiotics. Before use, cells were washed twice with Hank's balanced salt solution and treated with Accutase cell-detachment solution (Sigma-Aldrich). Cells were then washed with HBPS twice, and resuspended in HBPS. Peptides and controls were incubated with cells for at least 5 min before assays. The IonWorks software package was used for data acquisition and analysis, and the data were corrected for leak current. The decrease in current amplitude in the presence of the peptides was used to calculate the percentage blocking as follows:
where [CDP] is the concentration of the tested CDP, IC 50 is the concentration of the tested CDP producing half-maximal inhibition, N is the Hill coefficient, %VC is the percentage of the current rundown (the mean current inhibition at the vehicle control). and % block is the percentage of ion-channel current inhibited at each concentration of a test article. Controls, matched to particular channels, included ondansetron, mecamylamine, mibefradil dihydrochloride, picrotoxin, E-4031, BaCl 2 , 4-aminopyridine, verapamil, lidocaine, memantine and capsazepine (sourced from Sigma-Aldrich or Tocris). Nonlinear least-squares fits were solved with the XLfit add-in for Microsoft Excel.
Structure and sequence analyses. Sequence alignments and identity scores were determined with CLUSTALW 53 by using dynamic BLOSUM matrix selection. The phylogenetic analysis was performed with the MUSCLE alignment algorithm in the Geneious version 10.2.3 package, using default settings, the Jukes-Cantor genetic distance model and the UPGMA tree-building method 54, 55 . Threedimensional structure alignments were performed with Theseus 56,57 , and structure-based sequence alignment was performed with PROMALS3D 58 
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